temozolomide has been researched along with Delayed Hypersensitivity in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sampson, JH | 1 |
| Aldape, KD | 1 |
| Archer, GE | 1 |
| Coan, A | 1 |
| Desjardins, A | 1 |
| Friedman, AH | 1 |
| Friedman, HS | 1 |
| Gilbert, MR | 1 |
| Herndon, JE | 1 |
| McLendon, RE | 1 |
| Mitchell, DA | 1 |
| Reardon, DA | 1 |
| Sawaya, R | 1 |
| Schmittling, R | 1 |
| Shi, W | 1 |
| Vredenburgh, JJ | 1 |
| Bigner, DD | 1 |
| Heimberger, AB | 1 |
| Alonso-Llamazares, A | 1 |
| Vega-Castro, A | 1 |
| Beitia-Mazuecos, JM | 1 |
| Mateo-Borrega, B | 1 |
| Cardenas-Contreras, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Complementary Trial of an Immunotherapy Vaccine Against Tumor-Specific EGFRvIII[NCT00643097] | Phase 2 | 40 participants (Actual) | Interventional | 2007-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Time in months from the start of study treatment to the date of first progression according to Macdonald criteria, or to death due to any cause. Patients alive who had not progressed as of the last follow-up had PFS censored at the last follow-up date. Median PFS was estimated using a Kaplan-Meier curve.~Macdonald criteria are standard criteria in neuro-oncology. Tumor assessment was made according to the adapted MacDonald criteria based on the combined evaluation of: 1) assessment of the MRI scan for measurable, evaluable, and new lesions (made by the independent external expert too), 2) overall assessment of neurological performance (made by the investigator), 3) concomitant steroid use (as reported by the investigator)." (NCT00643097)
Timeframe: 58 months
| Intervention | months (Median) |
|---|---|
| Arm I (ACTIVATE) | 14.2 |
| Arm II (ACT II STD) | 12.1 |
| Arm III (ACT II DI) | 11.6 |
Number of patients that developed a delayed-type hypersensitivity (DTH) response at following vaccination. Any skin reaction in response to the intradermal injection of the antigen was measured and recorded. A positive skin test was defined as > 5 mm induration (swelling). (NCT00643097)
Timeframe: 26 months
| Intervention | participants (Number) |
|---|---|
| Arm I (ACTIVATE) | 3 |
| Arm II (ACT II STD) | 0 |
| Arm III (ACT II DI) | 7 |
The objective is to assess the duration of immunosuppressive cytokine secretion and to identify a receptive interval for active immunotherapy. Immunosuppression will determined by monitoring a panel of immunosuppressive serum/plasma cytokines longitudinally and by determining the response of each patient to Recombivax Hepatitis B (HB) vaccination. Response is defined as seropositive or seronegative to the Hepatitis B surface antigen. (NCT00643097)
Timeframe: 26 months
| Intervention | Months (Mean) |
|---|---|
| Arm I (ACTIVATE) | NA |
| Arm II (ACT II STD) | NA |
| Arm III (ACT II DI) | NA |
To assess for any potential toxicity to the PEP-3 vaccine immunization in patients with newly diagnosed glioblastoma, Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 was used to tabulate any toxicities attributable to PEP-3. The number of patients with toxicity attributable to vaccine while on study are tabulated. (NCT00643097)
Timeframe: 26 months
| Intervention | participants (Number) |
|---|---|
| Arm I (ACTIVATE) | 4 |
| Arm II (ACT II STD) | 1 |
| Arm III (ACT II DI) | 7 |
1 trial available for temozolomide and Delayed Hypersensitivity
| Article | Year |
|---|---|
Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Ad | 2011 |
1 other study available for temozolomide and Delayed Hypersensitivity
| Article | Year |
|---|---|
Rapid desensitization with temozolomide in patients with delayed maculopapular rash.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Desensitization, Immun | 2012 |